Home / Health / India's Diabetes & Obesity Drug Costs Plummet
India's Diabetes & Obesity Drug Costs Plummet
21 Mar
Summary
- Three major Indian pharma companies launched affordable semaglutide versions.
- New generic semaglutide offers hope for diabetes and obesity patients.
- Lower cost treatment options aim to improve patient access.
India has seen a significant development in diabetes and obesity treatment with the launch of lower-cost semaglutide injections. This move follows the recent expiration of the original drug's patent.
Three prominent Indian pharmaceutical firms—Sun Pharma, Zydus Lifesciences, and Dr Reddy's Laboratories—have released their own generic versions. Sun Pharma offers Noveltreat for weight management and Sematrinity for type 2 diabetes, with weekly costs ranging from Rs 750 to Rs 2,000.
Zydus Lifesciences has introduced SEMAGLYN, MASHEMA, and ALTERME using a reusable multi-dose pen, estimating a monthly treatment cost around Rs 2,200. Dr. Reddy's Laboratories launched Obeda, India's first DCGI-approved generic semaglutide injection for type 2 diabetes, priced at approximately Rs 4,200 per month.
Semaglutide, a GLP-1 receptor agonist, aids in controlling blood sugar and supporting weight loss. With over 100 million people living with diabetes in India, these more accessible treatment options are expected to greatly benefit a vast number of patients.
